Summary:
Gestalt and Primaa have partnered to integrate AI-powered dermatopathology tools into Gestalt’s PathFlow platform, enhancing skin cancer diagnostics with advanced automation and precision.
Takeaways:
- Enhanced Diagnostic Tools – Primaa’s AI technology aids pathologists in detecting and quantifying tumor biomarkers in skin tissues.
- Improved Workflow Efficiency – The integration streamlines diagnostic workflows, prioritizing high-risk cases for faster review.
- Commitment to Patient Care – The partnership aims to improve accuracy, efficiency, and patient outcomes in skin cancer diagnosis.
Gestalt, a digital pathology provider, and Primaa, a MedTech company specializing in AI-based dermatopathology solutions, announce a strategic partnership. This collaboration brings Primaa’s AI technology for skin cancer diagnosis directly into Gestalt’s acclaimed PathFlow platform. Together, they aim to create seamless workflows for pathologists while upholding the highest levels of diagnostic precision and patient safety.
Gestalt’s PathFlow is known for its versatility, supporting primary diagnoses*, education, resident training, and research workflows. By integrating Primaa’s advanced AI algorithms, the platform now empowers pathologists with enhanced tools for detecting and quantifying tumor biomarkers in skin tissues.
AI-Driven Algorithms Helps Detect All Forms of Skin Cancer
This integration allows pathologists to utilize AI-driven algorithms that detect critical biomarkers in skin lesions. Through the combined offering can automatically identify lesion types—including melanoma, squamous cell carcinoma, and basal cell carcinoma—and provides detailed measurements of lesion dimensions and margins. The solution also detects automatically all perineural invasions and all mitosis objects in the melanoma. Additionally, the system prioritizes high-risk cases for immediate review, ensuring timely and accurate diagnosis.
“Partnering with Primaa to integrate their skin AI technology into PathFlow underscores our dedication to providing pathologists with state-of-the-art tools,” says Lisa-Jean Clifford, COO & chief strategy officer of Gestalt. “This partnership represents a pivotal advancement in enhancing workflow efficiency and delivering superior patient care related to skin cancer.”
Fanny Sockeel, CEO at Primaa, adds, “Our collaboration with Gestalt, a leader in digital pathology, marks a significant step toward integrating AI seamlessly into pathologists’ workflows. Together, we aim to empower pathologists with cutting-edge technology that supports faster, more precise diagnoses, ultimately improving patient outcomes.”
Featured Image: Kateryna Kon | Dreamstime.com
*Following the LDT process in the US. It is under CE-IVD marking for use in Europe.
